Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...

Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...